Department of Surgery, Epidemiology and Biostatistics, Western University, London, Canada.
ICES Western, London, Canada.
Neurourol Urodyn. 2021 Jun;40(5):1200-1206. doi: 10.1002/nau.24682. Epub 2021 May 4.
Early reports have suggested that coronavirus disease 2019 (COVID-19) can present with significant urinary frequency and nocturia, and that these symptoms correlate with markers of inflammation in the urine. We evaluated surrogate markers of chronic urinary symptoms to determine if they were more frequent after COVID-19 infection.
Routinely collected data from the province of Ontario was used to conduct a matched, retrospective cohort study. We identified patients 66 years of age or older who had a positive COVID-19 test between February and May 2020 and survived at least 2 months after their diagnosis. We matched them to two similar patients who did not have a positive COVID-19 test during the same time period. We measured the frequency of urology consultation, cystoscopy, and new prescriptions for overactive bladder medications during a subsequent 3-month period. Proportional hazard models were adjusted for any baseline differences between the groups.
We matched 5617 patients with COVID-19 to 11,225 people who did not have COVID-19. The groups were similar, aside from a higher proportion of patients having hypertension and diabetes in the CoVID-19 cohort. There was no significantly increased hazard of new receipt of overactive bladder medication (hazards ratio [HR]: 1.04, p = 0.88), urology consultation (HR: 1.40, p = 0.10), or cystoscopy (HR: 1.14, p = 0.50) among patients who had COVID-19, compared to the matched cohort.
Surrogate markers of potential bladder dysfunction were not significantly increased in the 2-5 months after COVID-19 infection.
早期报告表明，2019 年冠状病毒病（COVID-19）可表现为明显的尿频和夜尿症，且这些症状与尿液中的炎症标志物相关。我们评估了潜在的慢性尿症状代标志物，以确定它们在 COVID-19 感染后是否更常见。
利用安大略省的常规收集数据进行了一项匹配的回顾性队列研究。我们确定了在 2020 年 2 月至 5 月之间 COVID-19 检测呈阳性且在诊断后至少存活 2 个月的 66 岁或以上的患者。我们将他们与在此期间 COVID-19 检测未呈阳性的 2 名相似患者进行匹配。在随后的 3 个月中，我们测量了泌尿科就诊，膀胱镜检查以及治疗膀胱过度活动症药物的新处方的频率。比例风险模型针对两组之间的任何基线差异进行了调整。
我们将 5617 名 COVID-19 患者与 11225 名未感染 COVID-19 的患者进行了匹配。除 COVID-19 队列中高血压和糖尿病患者的比例较高外，两组之间的差异无统计学意义。与匹配队列相比，COVID-19 患者新接受膀胱过度活动症药物（危险比[HR]：1.04，p=0.88），泌尿科就诊（HR：1.40，p=0.10）或膀胱镜检查（HR：1.14，p=0.50）的风险无明显增加。
在 COVID-19 感染后的 2-5 个月内，潜在膀胱功能障碍的替代标志物并未明显增加。
